Trial reportPediatric research2016
Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants.
Trial report in Pediatric research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Effects of Prebiotic Therapy on Gastrointestinal Microbiome of Individuals with Different Inflammatory Conditions: A Systematic Review of Randomized Controlled Trials.Probiotics and antimicrobial proteins · 2024Pooled it
- 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement.Foods (Basel, Switzerland) · 2026Review
- Gut dysbiosis and microbial metabolites in atopic dermatitis: implications for immune regulation along gut-skin axis.Frontiers in microbiology · 2026Review
- Breathable, wearable skin analyzer for reliable long-term monitoring of skin barrier function and individual environmental health impacts.Nature communications · 2025Article
- Probiotics and their metabolite spermidine enhance IFN-γCell reports. Medicine · 2024Article
- Characteristics of Gut Microbiota in Rosacea Patients-A Cross-Sectional, Controlled Pilot Study.Life (Basel, Switzerland) · 2024Article
- Review
- The prebiotic effect of 1-kestose in low-birth-weight neonates taking bifidobacteria: a pilot randomized trial in comparison with lactulose.Bioscience of microbiota, food and health · 2024Article
- Advanced fructo-oligosaccharides improve itching and aberrant epidermal lipid composition in children with atopic dermatitis.Frontiers in microbiology · 2024Article
- Dietary supplementation with 1-kestose induces altered locomotor activity and increased striatal dopamine levels with a change in gut microbiota in male mice.Physiological reports · 2023Article
- The Effect of Prebiotics on Atopic Dermatitis.Allergy, asthma & immunology research · 2023Article
- Bacterial Metabolites: A Link between Gut Microbiota and Dermatological Diseases.International journal of molecular sciences · 2023Review
- Review
- Enzymatic and structural characterization of β-fructofuranosidase from the honeybee gut bacterium Frischella perrara.Applied microbiology and biotechnology · 2022Article
- Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut.Nature microbiology · 2021Observational
- Nurturing the Early Life Gut Microbiome and Immune Maturation for Long Term Health.Microorganisms · 2021Review
- Activation of butyrate-producing bacteria as well as bifidobacteria in the cat intestinal microbiota by the administration of 1-kestose, the smallest component of fructo-oligosaccharide.The Journal of veterinary medical science · 2020Article
- A systematic machine learning and data type comparison yields metagenomic predictors of infant age, sex, breastfeeding, antibiotic usage, country of origin, and delivery type.PLoS computational biology · 2020Article
- Does the Gut Microbiota Modulate Host Physiology through Polymicrobial Biofilms?Microbes and environments · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough Faecalibacterium prausnitzii is a major bacterium in the intestine of adults, which is known to have anti-inflammatory effects, the development in infants or the response to prebiotics remains unclear.
methodsThe counts of F. prausnitzii in the feces were examined by real-time polymerase chain reaction (PCR). Fecal samples were obtained from 65 atopic dermatitis (AD) infants who participated in a randomized controlled clinical trial to investigate the therapeutic effect of kestose, the smallest fructooligosaccharide.
resultsAlthough the F. prausnitzii count was undetectable level in most 0- to 1-y-old infants, the count reached a level comparable to that in adults in 2- to 5-y-old infants. The bacterial number increased about 10-fold by oral administration of kestose every day for 12 wk in the younger infants, but not so much in the older infants. This bacterial increase was significantly correlated with an improvement in the AD symptoms in the older infants.
conclusionThe F. prausnitzii population in the intestine reaches a level comparable to that in adult at approximately 2 y of age. Kestose efficiently stimulates the growth of this bacterium in the intestine, which might lead to an improvement in AD symptoms in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.